GE Healthcare eyes $300 million opportunity with Flyrcado adoption in US, Evercore says

GE HealthCare Technologies

17/11/2025 14:07

** GE Healthcare GEHC.O says Cardiovascular Associates of America (CVAUSA), the largest network of private cardiology groups in the U.S., plans to broaden adoption of co's Flyrcado injection

** Flyrcado is a type of medical dye used during a heart scan to check how well the blood is flowing

** The deal with CVAUSA could lead to annualized revenue opportunity over time worth more than $300 mln- Evercore ISI

** CVAUSA says it plans to use Flyrcado across about 25 sites

** "While the pace of adoption across the 25 sites will determine time for GEHC to hit the peak >$300M revs, we think the economic incentives & image quality make a strong case for quicker adoption cycle"- Evercore

** Up to last close, stock down 6.4% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))